PMA P940010S009

Device
OPTIGUIDE PHOTODYNAMIC THERAPY FIBER OPTIC TREATMENT SYSTEM
Applicant
Pinnacle Biologics, Inc.
PMA number
P940010
Supplement
S009
Product code
MVG
Decision date
2000-09-29
Classification
System, Laser, Fiber Optic, Photodynamic Therapy
Generic name
System, laser, fiber optic, photodynamic therapy
Approval order statement
APPROVAL FOR MODIFICATION OF THE OPTIGUIDE FIBER OPTIC DIFFUSE TO INCLUDE USE OF A STERILE, SINGLE USE SHEATH WITH A REUSABLE DIFFUSING FIBER OPTIC. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME OPTIGUIDE PHOTODYNAMIC THERAPY FIBER OPTIC TREATMENT SYSTEM, SERIES DCYL 4 AND IS INDICATED FOR USE IN PHOTODYNAMIC THERAPY WITH PHOTOFRIN(R) (PORFIMER SODIUM) FOR INJECTION FOR THE: 1) PALLIATION OF PATIENTS WITH COMPLETELY OBSTRUCTING ESOPHAGEAL CANCER, OR OF PATIENTS WITH PARTIALLY OBSTRUCTING ESOPHAGEAL CANCER WHO, IN THE OPINION OF THEIR PHYSICIANS, CANNOT BE SATISFACTORILY TREATED WITH ND:YAG LASER THERAPY, 2) REDUCTION OF OBSTTUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER (NSCLC), 3) TREATMENT OF MICROINVASIVE ENDOBRONCHIAL NSCLC IN PATIENTS OF WHOM SURGERY AND RADIOTHERAPY ARE NOT INDICATED.

Current openFDA PMA Record#

Device
OPTIGUIDE PHOTODYNAMIC THERAPY FIBER OPTIC TREATMENT SYSTEM
Applicant
Pinnacle Biologics, Inc.
PMA number
P940010
Supplement
S009
Product code
MVG
Generic name
System, laser, fiber optic, photodynamic therapy
Decision date
2000-09-29
Decision code
APPR
Date received
2000-04-17
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Approval order statement
APPROVAL FOR MODIFICATION OF THE OPTIGUIDE FIBER OPTIC DIFFUSE TO INCLUDE USE OF A STERILE, SINGLE USE SHEATH WITH A REUSABLE DIFFUSING FIBER OPTIC. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME OPTIGUIDE PHOTODYNAMIC THERAPY FIBER OPTIC TREATMENT SYSTEM, SERIES DCYL 4 AND IS INDICATED FOR USE IN PHOTODYNAMIC THERAPY WITH PHOTOFRIN(R) (PORFIMER SODIUM) FOR INJECTION FOR THE: 1) PALLIATION OF PATIENTS WITH COMPLETELY OBSTRUCTING ESOPHAGEAL CANCER, OR OF PATIENTS WITH PARTIALLY OBSTRUCTING ESOPHAGEAL CANCER WHO, IN THE OPINION OF THEIR PHYSICIANS, CANNOT BE SATISFACTORILY TREATED WITH ND:YAG LASER THERAPY, 2) REDUCTION OF OBSTTUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER (NSCLC), 3) TREATMENT OF MICROINVASIVE ENDOBRONCHIAL NSCLC IN PATIENTS OF WHOM SURGERY AND RADIOTHERAPY ARE NOT INDICATED.